Literature DB >> 31269829

Antibody responses to yellow fever vaccine in 9 to 11-month-old Malian and Ghanaian children.

Olubukola T Idoko1,2, Nuredin Mohammed1, Patrick Ansah3, Abraham Hodgson3, Milagritos D Tapia4, Samba O Sow4, Paanchali R Chowdhury5, Matthias Niedrig5, Elmar Saathoff6,7, Beate Kampmann1,8.   

Abstract

Background: The World Health Organization recommends use of a single yellow fever (YF) vaccine dose for life and fractional doses in outbreaks when there are limited vaccine stocks. In endemic regions, this vaccine is given as part of routine infant immunization programs around 9 months of age. There is a need to better understand immune responses when vaccinating infants particularly in contexts where the child may be malnourished.
Methods: Data from 393 Malian and Ghanaian infants who concomitantly received measles and YF vaccines at 9 to 11 months of age were retrospectively analyzed. Response to YF vaccine was examined for association with nutritional status at time of vaccination, sex, age, pre-vaccination titers and season of vaccination.
Results: Neutralizing antibodies following vaccination were unaffected by season of vaccination, sex, pre-vaccination titers or nutritional status, though there was a trend to higher titers in males and children with higher height for age z-scores. Seroconversion rates differed significantly between countries (63.5 in Ghana vs. 91.0% in Mali).
Conclusion: Longitudinal, prospective studies are needed to optimize the use of YF vaccine in infants in endemic settings. There may be a need for booster vaccinations and to compare various vaccine preparations to optimize the use of available vaccines.

Entities:  

Keywords:  African; Neutralizing antibody; infant; vaccine; yellow fever (YF)

Mesh:

Substances:

Year:  2019        PMID: 31269829     DOI: 10.1080/14760584.2019.1640118

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  6 in total

Review 1.  Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection.

Authors:  J Erin Staples; Alan D T Barrett; Annelies Wilder-Smith; Joachim Hombach
Journal:  NPJ Vaccines       Date:  2020-07-06       Impact factor: 7.344

Review 2.  Yellow Fever in Travelers.

Authors:  Annelies Wilder-Smith
Journal:  Curr Infect Dis Rep       Date:  2019-10-31       Impact factor: 3.725

3.  Serological Protection 5-6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes.

Authors:  Olubukola T Idoko; Cristina Domingo; Milagritos D Tapia; Samba O Sow; Christof Geldmacher; Elmar Saathoff; Beate Kampmann
Journal:  Front Immunol       Date:  2020-10-08       Impact factor: 7.561

Review 4.  What Constitutes Protective Immunity Following Yellow Fever Vaccination?

Authors:  Jolynne Mokaya; Derick Kimathi; Teresa Lambe; George M Warimwe
Journal:  Vaccines (Basel)       Date:  2021-06-18

Review 5.  Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection.

Authors:  J Erin Staples; Alan D T Barrett; Annelies Wilder-Smith; Joachim Hombach
Journal:  NPJ Vaccines       Date:  2020-07-06       Impact factor: 7.344

6.  Towards Precision Vaccines: Lessons From the Second International Precision Vaccines Conference.

Authors:  Dheeraj Soni; Simon D Van Haren; Olubukola T Idoko; Jay T Evans; Joann Diray-Arce; David J Dowling; Ofer Levy
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.